Scholarlink

Purpose <p>The newly discovered histone methyltransferase KMT9 serves as an epigenetic regulator of carcinogenesis in various cancer entities. For the first time, we investigated the presence of KMT9α in cholangiocarcinoma, the association with histologic subtypes, and its impact on survival.</p> Methods <p>A tissue microarray cohort of all CCA patients who underwent surgical resection with curative intent between 08/2005 and 12/2021 at the University Hospital Frankfurt was immunohistochemically analyzed with the KMT9α antibody. For overall survival, Kaplan–Meier curves and Cox-regression analyses were performed.</p> Results <p>In total, 174 patients were suitable for IHC analysis. Of the patients, 35.1% (<i>n</i> = 61) overexpressed KMT9α. Kaplan-Meier curves revealed a median OS of 34.75 months (95% CI = 20.23–49.27 months) for all CCA patients positive for KMT9α in comparison to 54.21 months (95% CI = 41.78–66.63 months) for patients lacking KMT9α overexpression (<i>p</i> = 0.004). Subtype analysis revealed strong differences in KMT9α expression. Multivariate Cox regression analysis identified KMT9α as an independent risk factor for shorter OS in CCA.</p> Conclusion <p>This study demonstrates that a marked subset of CCA patients exhibit overexpression of KMT9α. These findings underscore the prognostic significance of KMT9α and reinforce its potential as a therapeutic target, consistent with its role in other cancer types.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Overexpression of KMT9α is associated with poor outcome in cholangiocarcinoma patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月13日

查看全文
  • Maximilian N. Kinzler,
  • Eric Metzger,
  • Rebecca Schulz,
  • Katrin Bankov,
  • Anna Ramos-Triguero,
  • Falko Schulze,
  • Steffen Gretser,
  • Nada Abedin,
  • Armin Wiegering,
  • Stefan Zeuzem,
  • Dirk Walter,
  • Henning Reis,
  • Roland Schüle,
  • Peter J. Wild

摘要

Purpose

The newly discovered histone methyltransferase KMT9 serves as an epigenetic regulator of carcinogenesis in various cancer entities. For the first time, we investigated the presence of KMT9α in cholangiocarcinoma, the association with histologic subtypes, and its impact on survival.

Methods

A tissue microarray cohort of all CCA patients who underwent surgical resection with curative intent between 08/2005 and 12/2021 at the University Hospital Frankfurt was immunohistochemically analyzed with the KMT9α antibody. For overall survival, Kaplan–Meier curves and Cox-regression analyses were performed.

Results

In total, 174 patients were suitable for IHC analysis. Of the patients, 35.1% (n = 61) overexpressed KMT9α. Kaplan-Meier curves revealed a median OS of 34.75 months (95% CI = 20.23–49.27 months) for all CCA patients positive for KMT9α in comparison to 54.21 months (95% CI = 41.78–66.63 months) for patients lacking KMT9α overexpression (p = 0.004). Subtype analysis revealed strong differences in KMT9α expression. Multivariate Cox regression analysis identified KMT9α as an independent risk factor for shorter OS in CCA.

Conclusion

This study demonstrates that a marked subset of CCA patients exhibit overexpression of KMT9α. These findings underscore the prognostic significance of KMT9α and reinforce its potential as a therapeutic target, consistent with its role in other cancer types.